Abstract
Background: Atherosclerotic Cardiovascular Disease (ASCVD) is the first cause of death in Western Countries. Several risk factors contribute to generate atherosclerosis and the preventive therapeutic approaches, in particular statin therapy, reduce the mortality. However, the residual risk in statin treated patients remains significant, despite reaching the low density lipoproteins cholesterol (LDL-C) goals.
Methods: we reviewed the literature published in PUB-MED to discuss the role of residual dyslipidemia in particular high density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and lipoprotein(a) [Lp(a)], genetic factors, suboptimal implementation of lifestyle therapy, mood disorders associated to low compliance to application of evidence-based therapies or related to ASCVD.
Results: we summarized the current knowledge on the topic, evidencing its contradictory aspects.
Conclusion: HDL-C is an important biomarker for predicting cardiovascular risk, but the classical HDL hypothesis is no longer correct and it is now being replaced by the HDL function hypothesis, thought more studies are needed to validate it. The connection between cardiovascular risk and levels of TGs is not so definite. APOE genotype and Lp(a) levels are two genetics factors associated to CV risk. Healthy lifestyle with particular dietetic factors, connected to psychological aspects, are very important for the optimal control of the global risk.
Keywords: Residual risk, lipid-lowering therapy, atherogenic dyslipidemia, genetic risk, correct lifestyle, cardiovascular prevention.
Current Pharmaceutical Design
Title:Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Volume: 22 Issue: 37
Author(s): Giulia Bruzzone, Giorgia Corbelli, Paola Belci, Annalaura Cremonini, Aldo Pende and Livia Pisciotta
Affiliation:
Keywords: Residual risk, lipid-lowering therapy, atherogenic dyslipidemia, genetic risk, correct lifestyle, cardiovascular prevention.
Abstract: Background: Atherosclerotic Cardiovascular Disease (ASCVD) is the first cause of death in Western Countries. Several risk factors contribute to generate atherosclerosis and the preventive therapeutic approaches, in particular statin therapy, reduce the mortality. However, the residual risk in statin treated patients remains significant, despite reaching the low density lipoproteins cholesterol (LDL-C) goals.
Methods: we reviewed the literature published in PUB-MED to discuss the role of residual dyslipidemia in particular high density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and lipoprotein(a) [Lp(a)], genetic factors, suboptimal implementation of lifestyle therapy, mood disorders associated to low compliance to application of evidence-based therapies or related to ASCVD.
Results: we summarized the current knowledge on the topic, evidencing its contradictory aspects.
Conclusion: HDL-C is an important biomarker for predicting cardiovascular risk, but the classical HDL hypothesis is no longer correct and it is now being replaced by the HDL function hypothesis, thought more studies are needed to validate it. The connection between cardiovascular risk and levels of TGs is not so definite. APOE genotype and Lp(a) levels are two genetics factors associated to CV risk. Healthy lifestyle with particular dietetic factors, connected to psychological aspects, are very important for the optimal control of the global risk.
Export Options
About this article
Cite this article as:
Bruzzone Giulia, Corbelli Giorgia, Belci Paola, Cremonini Annalaura, Pende Aldo and Pisciotta Livia, Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk, Current Pharmaceutical Design 2016; 22 (37) . https://dx.doi.org/10.2174/1381612822666160822143753
DOI https://dx.doi.org/10.2174/1381612822666160822143753 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design Patients with Rheumatic Diseases Overlooked during COVID-19 Pandemic: How are They Doing and Behaving?
Current Rheumatology Reviews Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology Contrast Media in Cardiovascular Magnetic Resonance
Current Pharmaceutical Design The Relationship Between Diabetes Mellitus, Geriatric Syndromes, Physical Function, and Gait: A Review of the Literature
Current Diabetes Reviews Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Contrast Medium Induced Nephropathy: New Insights into Prevention and Risk Management
Cardiovascular & Hematological Agents in Medicinal Chemistry ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Atherogenesis in White Coat Hypertension
Current Hypertension Reviews Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Platelet Hyperreactivity and Stent Thrombosis in Patients Undergoing Coronary Stenting
Current Vascular Pharmacology